Sima Sistani, the boss of WeightWatchers, has quit as the dieting firm struggles to compete with the growing demand for 'fat ...

WeightWatchers announced Friday that CEO Sima Sistani is no longer at the company, and independent board member Tara Comonte ...

About 40% of U.S. adults suffer from obesity, and the cost of covering GLP-1 agonists and related anti-obesity drugs can be ...

Sima Sistani, who took up the CEO post at WW International two-and-a-half years ago, is out, according to the company.

Nestle launched frozen meals tailored for people on weight-loss drugs like Ozempic and Wegovy. We tried the teriyaki chicken ...

Sima Sistani helped push the company into the GLP-1 drug space with the $106 million acquisition of Sequence.

GLP-1 medications—like Ozempic, Wegovy, and Zepbound—can help you shed pounds, but only if taken properly. Don't get caught ...

WeightWatchers CEO Sima Sistani, who pushed the company into embracing weight-loss drugs, is leaving the position after a two ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

On Capitol Hill lawmakers grilled the CEO of the company that makes popular weight loss drugs Ozempic and Wegovy.

In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...

A new study published in JAMA Network Open contends that women may lose more weight on semaglutides like Ozempic than men.